(Q37856242)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21428462%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

review article

1 reference

title

Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21428462%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21428462%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

C Robert Bernardino

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21428462%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

1 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21428462%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21428462%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21428462%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21428462%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

267-282

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21428462%20AND%20SRC:MED&resulttype=core&format=json

An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma

26 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Prevalence of open-angle glaucoma among adults in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Conjunctival changes associated with glaucoma therapy: implications for the external disease consultant and the treatment of glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Effects of common ophthalmic preservatives on ocular health

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

The conjunctival epithelium in dry eye subtypes: effect of preserved and non-preserved topical treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Ocular tolerance of absorption enhancers in ophthalmic preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Pilocarpine permeability across ocular tissues and cell cultures: influence of formulation parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Corneal toxicity secondary to inadvertent use of benzalkonium chloride preserved viscoelastic material in cataract surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Antimicrobial efficacy assessment of multi-use solution to disinfect hydrophilic contact lens, in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

An investigation into the antimicrobial mechanisms of action of two contact lens biocides using electron microscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Aspects of the antimicrobial mechanisms of action of a polyquaternium and an amidoamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Effects of switching to SofZia-preserved travoprost in patients who presented with superficial punctate keratopathy while under treatment with latanoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Betaxolol eye drops. A clinical trial of safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Ocular metipranolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Allergic contact conjunctivitis due to timolol in eyedrops

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Allergic contact dermatitis due to beta-blockers in eye drops: a retrospective analysis of multicentre surveillance data 1993-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Allergic contact dermatitis from timolol and dorzolamide eye drops

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Allergic contact dermatitis due to the beta-blocker betaxolol in eyedrops, with cross-sensitivity to timolol.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Drug-induced pemphigoid. A spectrum of diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Metipranolol-induced adverse reactions: I. The rechallenge study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Lichenoid drug eruption secondary to topical timolol and dorzolamide eye-drops.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Topical glaucoma therapy as a risk factor for nasolacrimal duct obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Topical antiglaucoma medications and lacrimal drainage system obstruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Effects of beta-adrenergic antagonist on width of nasolacrimal drainage system lumen

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Effects of topical timolol (0.5%) and betaxolol (0.5%) on corneal sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Effect of beta-blocker eyedrops on corneal epithelial barrier function.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Comparison of the Effects of Topical Levobunolol and Timolol Solution on the Human Ocular Surface

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Effect of clonidine on aqueous humor flow in normal human eyes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Chronic use of apraclonidine decreases its moderation of post-laser intraocular pressure spikes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Long term effect of apraclonidine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Iopidine allergy causing lower eyelid ectropion progressing to cicatricial entropion

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Allergic contact dermatitis from apraclonidine in eyedrops

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

A proposed mechanism for p-aminoclonidine allergenicity based on its relative oxidative lability

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

The efficacy of 0.2% brimonidine for preventing intraocular pressure rise following argon laser trabeculoplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Alphagan allergy may increase the propensity for multiple eye-drop allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Drug-induced ectropion: what is best practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Reversible cicatricial ectropion precipitated by topical brimonidine eye drops

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

The teardrop sign: a rare dermatological reaction to brimonidine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Dermatological Side Effects of Brimonidine: A Report of Three Cases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Unilateral allergic contact dermatitis of the eyelid caused by Iopimax

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Systemic contact dermatitis to dorzolamide eye drops

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Contact dermatitis caused by allergy to dorzolamide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Allergic contact dermatitis due to dorzolamide eyedrops

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Periorbital dermatitis as a side effect of topical dorzolamide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Erythema multiforme after use of topical dorzolamide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

An unusual appearance of limbal conjunctival follicles in a patient on brimonidine and dorzolamide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Allergic contact blepharoconjunctivitis from dorzolamide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Endothelial changes associated with topical dorzolamide do appear to be significant

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Corneal edema in glaucoma patients after the addition of brinzolamide 1% ophthalmic suspension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Brinzolamide induced reversible corneal decompensation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Irreversible corneal decompensation in patients treated with topical dorzolamide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

The effects of combination glaucoma medications on ocular surface epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Miotics: side effects and ways to avoid them

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Differentiating conjunctivitis of diverse origins

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Glaucoma in patients with ocular cicatricial pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Extensive facial skin pigmentation after latanoprost treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Contact dermatitis caused by latanoprost-containing eye drops with good tolerance to bimatoprost eye drops.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Allergic contact dermatitis to latanoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Contact dermatitis from topical bimatoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Herpes simplex virus dermatitis in patients using latanoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Latanoprost and hyperpigmentation of eyelashes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Intermittent blurred vision and trichomegaly due to latanoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Latanoprost stimulates secretion of matrix metalloproteinases in tenon fibroblasts both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Latanoprost and herpes simplex keratitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Putative side effects of prostaglandin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Herpes simplex dendritic keratitis after treatment with latanoprost for primary open angle glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Induction of tyrosinase gene transcription in human iris organ cultures exposed to latanoprost.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Mechanism and clinical significance of prostaglandin-induced iris pigmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Allergic contact dermatitis from cross-reacting beta-blocking agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11588830-000000000-00000

Apraclonidine. A one-week dose-response study

21 January 2018

1 reference

12 December 2020

Effect of topical apraclonidine on the frequency of intraocular pressure elevations after combined extracapsular cataract extraction and trabeculectomy

1 reference

12 December 2020

Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy

1 reference

12 December 2020

Allergic conjunctivitis associated with timolol therapy in an adult

1 reference

12 December 2020

The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva

1 reference

12 December 2020

Allergic contact dermatitis to timolol

1 reference

12 December 2020

Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group

1 reference

12 December 2020

Increased eyelid pigmentation associated with use of latanoprost

1 reference

12 December 2020

Effects of brimonidine on aqueous humor dynamics in human eyes

1 reference

12 December 2020

Eyelash formation secondary to latanoprost treatment in a patient with alopecia

1 reference

12 December 2020

Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145)

1 reference

12 December 2020

[Change in corneal sensitivity after topical dorzolamide administration. A comparative study]

1 reference

12 December 2020

Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens

1 reference

12 December 2020

Mechanisms of failure in glaucoma filtering surgery: a consequence of antiglaucomatous drugs?

1 reference

12 December 2020

A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group

1 reference

12 December 2020

Mechanism of blurred vision after brinzolamide instillation

1 reference

12 December 2020

Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study

1 reference

12 December 2020

Time course of changes in contrast sensitivity function after application of antiglaucomatous eyedrops

1 reference

12 December 2020

Contact dermatitis from levobunolol eyedrops

1 reference

12 December 2020

Contact allergy to beta-blocking agents in ophthalmic preparations

1 reference

12 December 2020

Recurrent corneal keratitis associated with the use of latanoprost

1 reference

12 December 2020

Corneal anesthesia after timolol maleate therapy

1 reference

12 December 2020

Glaucoma treatment with once-daily levobunolol

1 reference

12 December 2020

Sensitization to levobunolol eyedrops

1 reference

12 December 2020

Apraclonidine 0.5% versus 1% for controlling intraocular pressure elevation after argon laser trabeculoplasty

1 reference

12 December 2020

Cytometric assessment of cytostatic and cytotoxic effects of topical glaucoma medications on human epithelial corneal line cells

1 reference

12 December 2020

Effect of anti-glaucoma eyedrops on cell differentiation of the conjunctiva

1 reference

12 December 2020

Evidence of early change in iris color with latanoprost use

1 reference

12 December 2020

Drug-induced cicatricial pemphigoid affecting the conjunctiva. Light and electron microscopic features

1 reference

12 December 2020

[Goblet cell density modified by pilocarpine]

1 reference

12 December 2020

Follicular conjunctivitis associated with apraclonidine

1 reference

12 December 2020

Allergic contact dermatitis from timolol complicating choroidal melanoma-related glaucoma

1 reference

12 December 2020

Interleukin-1beta tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers

1 reference

12 December 2020

Darkening of eyelashes in a patient treated with latanoprost

1 reference

12 December 2020

The effect of latanoprost and brimonidine on rabbit subconjunctival fibroblasts

1 reference

12 December 2020

[Erosive marginal keratitis due to pilocarpine allergy]

1 reference

12 December 2020

Timolol treatment of chronic open-angle glaucoma and ocular hypertension. A 2.5-year multicenter study

1 reference

12 December 2020

Herpetic keratitis in a patient who used two different prostaglandin analogue ophthalmic solutions: a case report.

1 reference

12 December 2020

Toxic epidermal necrolysis following dorzolamide eyedrops

1 reference

12 December 2020

Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells.

1 reference

12 December 2020

Contact dermatitis by timolol

1 reference

12 December 2020

Pilocarpine-associated allograft rejection in postkeratoplasty patients

1 reference

12 December 2020

Multiple-dose, dose-response relationship for the topical carbonic anhydrase inhibitor MK-927

1 reference

12 December 2020

Prophylactic use of apraclonidine for intraocular pressure increase after Nd:YAG capsulotomies

1 reference

12 December 2020

A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma.

1 reference

12 December 2020

Apraclonidine and argon laser trabeculoplasty

1 reference

12 December 2020

Ocular surface disfunction in glaucoma

1 reference

12 December 2020

Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients

1 reference

12 December 2020

Latanoprost and periocular skin color changes.

1 reference

12 December 2020

Squamous metaplasia or epidermalization of the conjunctiva as an adverse reaction to topical medication

1 reference

12 December 2020

Eczema of the eyelids caused by pilocarpine

1 reference

12 December 2020

Allergic contact dermatitis from pilocarpine and thimerosal

1 reference

12 December 2020

Update in glaucoma: the new pharmacotherapies. Brimonidine versus apraclonidine

1 reference

12 December 2020

Short-term Effects of Unilateral 1% Apraclonidine Therapy

1 reference

12 December 2020

Recurrence of bilateral herpes simplex virus keratitis following bimatoprost use.

1 reference

12 December 2020

[Latanoprost-associated recurrent herpes simplex keratitis]

1 reference

12 December 2020

Iris-color change developed after topical isopropyl unoprostone treatment

1 reference

12 December 2020

A One-Year Multicenter Clinical Trial of Pilocarpine Gel

1 reference

12 December 2020

Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect

1 reference

12 December 2020

Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost

1 reference

12 December 2020

Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells.

1 reference

12 December 2020

High incidence of topical allergic reactions to 1% apraclonidine

1 reference

12 December 2020

A comparative study of Ocusert Pilo 40, intensive pilocarpine and low-dose pilocarpine in the initial treatment of primary acute angle-closure glaucoma

1 reference

12 December 2020

Toxic effects of topically administered Betagan, Betoptic, and Timoptic on regenerating corneal epithelium.

1 reference

12 December 2020

Pilocarpine toxicity. Effects on the rabbit corneal endothelium

1 reference

12 December 2020

Allergic contact dermatitis caused by latanoprost ophthalmic solution

1 reference

12 December 2020

Sterile mucopurulent conjunctivitis associated with the use of dorzolamide eyedrops

1 reference

12 December 2020

The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.

1 reference

12 December 2020

Combination of systemic acetazolamide and topical dorzolamide

1 reference

12 December 2020

Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies

1 reference

12 December 2020

Contact dermatitis from pilocarpine

1 reference

12 December 2020

Pilocarpine allergic contact and photocontact dermatitis

1 reference

12 December 2020

A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III

1 reference

12 December 2020

Corneal descompensation in patients with endothelial compromise treated with topical dorzolamide

1 reference

12 December 2020

Contact allergy to dorzolamide eyedrops

1 reference

12 December 2020

Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit

1 reference

12 December 2020

Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group.

1 reference

12 December 2020

Structural and immunohistochemical changes of conjunctiva induced by topical glaucoma medication

1 reference

12 December 2020

Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group

1 reference

12 December 2020

Corneal changes during pilocarpine gel therapy.

1 reference

12 December 2020

Incidence of brimonidine allergy in patients previously allergic to apraclonidine.

1 reference

12 December 2020

Lacrimal canalicular obstruction associated with topical ocular medication

1 reference

12 December 2020

The influence of topical beta-blockers on the breakup time

1 reference

12 December 2020

Preclinical overview of brinzolamide

1 reference

12 December 2020

A multicenter evaluation of levobunolol (Vistagan) in Germany

1 reference

12 December 2020

Corneal toxicity associated with latanoprost

1 reference

12 December 2020

Allergic contact dermatitis from apraclonidine

1 reference

12 December 2020

[Contact allergy to eyedrops containing beta-blockers]

1 reference

12 December 2020

Impression cytology of the conjunctival epithelium after antiglaucomatous treatment with latanoprost.

1 reference

12 December 2020

Effect of latanoprost and timolol on the histopathology of the rabbit conjunctiva

1 reference

12 December 2020

Effects of apraclonidine on intraocular pressure and blood-aqueous barrier permeability after phacoemulsification and intraocular lens implantation

1 reference

12 December 2020

10.2165/11588830-000000000-00000

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21428462%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference